Revised Recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia

Journal of Clinical Oncology

Volumn 21, Issue 24, 2003, Pages 4642-4649

  Cheson, Bruce D ^a   Bennett, John M ^b   Kopecky, Kenneth J ^b   Büchner, Thomas ^b   Willman, Cheryl L ^b   Estey, Elihu H ^b   Schiffer, Charles A ^b   Doehner, Hartmut ^b   Tallman, Martin S ^b   Lister, T Andrew ^b   LoCocco, Francesco ^b   Willemze, Roel ^b   Biondi, Andrea ^b   Hiddemann, Wolfgang ^b   Larson, Richard A ^b   Löwenberg, Bob ^b   Sanz, Miguel A ^b   Head, David R ^b   Ohno, Ryuzo ^b   Bloomfield, Clara D ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER GENETICS; CANCER REGRESSION; CYTOGENETICS; HUMAN; PRIORITY JOURNAL; PUBLICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CLASSIFICATION; CLINICAL TRIAL; PRACTICE GUIDELINE; REMISSION; STANDARD; UNITED STATES;

CLINICAL TRIALS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; REMISSION INDUCTION; UNITED STATES;

EID: 1542753559     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.036     Document Type: Article

References (44)

1. Cheson BD, Cassileth PA, Head DR, et al: Report of the NCI-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
2. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias: French-American-British (FAB) Co-Operative Group. Br J Haematol 33:451-458, 1976
3. Bennett JM, Catovsky D, Daniel MT, et al: Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). Ann Intern Med 103:460-462, 1985
4. Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:626-629, 1985
5. Bennett JM, Catovsky D, Daniel MT, et al: Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-MO). Br J Haematol 78:325-329, 1991
6. Jaffe ES, Harris NL, Stein H, et al: Tumours of Haematopoietic and Lymphoid Tissues, World Health Organization Classification of Tumours: Pathology & Genetics. Lyon, France, IARC Press, 2001.
7. Vardiman J, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302, 2002
8. Bennett JM: Secondary acute myeloid leukemia [editorial]. Leuk Res 19:231-232, 1995
9. Smith SM, Le Beau MM, Huo D, et al: Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago experience. Blood 102:43-52, 2003
10. Quesnel B, Kantarjian H, Bjergaard JP, et al: Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): A report on 25 cases and review of the literature. J Clin Oncol 11:2370-2379, 1993
11. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting-Airlie House, Virginia. J Clin Oncol 17:3835-3849, 1999
12. Goasguen JE, Matsuo T, Cox C, et al: Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: Major importance of dysgranulopoiesis for remission and survival. Leukemia 6:520-525, 1992
13. Gahn B, Haase D, Unterhalt M, et al: De novo AML with dysplastic hematopoiesis: Cytogenetic and prognostic significance. Leukemia 10:946-951, 1996
14. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998
15. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative index of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
16. Estey E, Keating MJ, Pierce S, et al: Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. Leukemia 9:972-976, 1995
17. Whitman SP, Archer KJ, Feng L, et al: Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A cancer and leukemia group B study. Cancer Res 61:7233-7239, 2001
18. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002
19. Fröhling S, Schlenk RF, Breitruck J, et al: Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 100:4372-4380, 2002
20. Döhner K, Tobis K, Ulrich R, et al: Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetic: A study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 20:3254-3261, 2002
21. Caligiuri MA, Strout MP, Lawrence D, et al: Rearrangements of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58:55-59, 1998
22. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans retinoic in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100:4298-4302, 2002
23. Büchner T, Hiddemann W, Wörmann B, et al: Double induction strategy for acute myeloid leukemia: The effects of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanins-A randomized trial by the German AML Cooperative Group. Blood 93:4116-4124, 1999
24. Kern W, Haferlach T, Schoch C, et al: Early blast clearance during aplasia following induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: Data from the German AML Cooperative Group trial 1992. Blood 98:462a, 2001 (abstr 1932)
25. Estey EH, Kantarjian HM, Cortes JE, et al: Is the absence of circulating blasts a valid criterion for CR in AML? Blood 100:88a, 2002 (abstr 324)
26. Estey EH, Thall PF, Wang X, et al: Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. Blood 102:3097-3099, 2003
27. Marcucci G, Archer KJ, Mrózek K, et al: Abnormal karyotype during complete remission (CR) predicts short relapse-free survival (RFS) in acute myeloid leukemia (AML): Results from CALGB 8461. Blood 98:577a, 2001 (abstr-2421)
28. Freireich EJ, Cork A, Stass SA, et al: Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia 6:500-506, 1992
29. Baer MR, Stewart CC, Dodge RK, et al: High frequency of immunophenotypic changes in acute myeloid leukemia at relapse: Implications for residual disease detection (Cancer and Leukemia Group B study 8361). Blood 97:3574-3580, 2001
30. Diverio D, Rossi V, Avvisati G, et al: Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR-alpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood 92:784-789, 1998
31. Jurcic JG, Nimer SD, Scheinberg DA, et al: Prognostic significance of minimal residual disease and PML/RAR-alpha isoform type: Long-term follow-up in acute promyelocytic leukemia. Blood 98:2651-2656, 2001
32. Cilloni D, Gottardi E, De Micheli D, et al: Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16:2115-2121, 2002
33. Sievers EL, Larson RA, Stadtmauer EA, et al: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244-3254, 2001
34. Lopez G, Giles F, Cortes J, et al: Sub-types of resistant disease in patients with AML, RAEB-t, or RAEB who fail initial induction chemotherapy. Blood 98:329a, 2001 (abstr 1388)
35. Estey E, Pierce S: Routine bone marrow exam during first remission of acute myeloid leukemia. Blood 87:3899-3902, 1996
36. Burnett AK, Grimwade D, Solomon E, et al: Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the Randomized MRC Trial. Blood 93:4131-4143, 1999
37. Gallagher RE, Yeap BY, Bi W, et al: Quantitative real-time RT-PCR analysis of PML-RAR-alpha mRNA in acute promyelocytic leukemia: Assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 101:2521-2528, 2003
38. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
39. Gooley TA, Leisenring W, Crowley J, et al: Why Kaplan-Meier fails and cumulative index succeeds when estimating failure probabilities in the presence of competing risks, in Crowley J (ed): Handbook of Statistics in Clinical Oncology. New York, NY, Marcel Dekker, 2001, pp 513-524
40. Pepe MS, Mori M: Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data. Stat Med 12:737-751, 1993
41. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
42. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
43. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
44. de Lima M, Strom SS, Keating M, et al: Implications of potential cure in acute myelogenous leukemia: Development of subsequent cancer and return to work. Blood 90:4719-4724, 1997